ADHD is common, lifelong and highly variable.

It is a neurodevelopmental condition characterised by persistent patterns of inattention and/or hyperactivity-impulsivity that begin in childhood, occur across settings and cause meaningful impairment. ADHD can affect education, work, relationships, finances, sleep, driving, physical health and emotional wellbeing — but timely recognition, appropriate treatment and the right environment can make a major difference.

1. ADHD in one page

What it is

A neurodevelopmental condition involving development and regulation of attention, activity, impulse control and executive functions.

Core diagnostic domains

Inattention and hyperactivity/impulsivity. Adults may experience internal restlessness rather than obvious motor hyperactivity.

When it starts

Symptoms must have roots in childhood. Adult diagnosis can be made later, but the disorder itself does not first begin in middle age.

Where it appears

A clinically meaningful pattern should be evident across more than one setting, such as home, education, relationships or work.

What diagnosis requires

Symptoms alone are not enough: there must be impairment, developmental history, differential diagnosis and assessment of coexisting conditions.

What treatment can do

Medication, psychoeducation, psychological approaches, coaching/skills support and environmental adjustments can reduce impairment and improve functioning.

A useful way to think about ADHD

ADHD is not simply “poor concentration”. Attention in ADHD is often inconsistent and context-dependent. Many people can focus intensely on something novel, urgent, rewarding or personally meaningful while struggling to initiate, sustain or finish routine tasks. The clinical problem is not an absolute inability to pay attention; it is difficulty regulating attention and behaviour reliably in line with goals.

The central question is functional impact.

A diagnosis is not based on personality traits, internet checklists, school reports alone, or whether someone can occasionally concentrate. Assessment asks whether a persistent developmental pattern is causing clinically significant impairment and is not better explained by another condition.

2. What ADHD is — and what it is not

Modern evidence supports ADHD as a valid neurodevelopmental disorder with substantial genetic contribution and measurable group-level differences in brain development and function. No single scan, blood test, gene or computerised attention test can diagnose ADHD in an individual. Diagnosis remains clinical.

ADHD is not:

• a consequence of bad parenting, laziness, low intelligence or weak character;

• a diagnosis made solely because someone is distracted by phones, social media or modern life;

• defined by one neurotransmitter being simply “too low”;

• excluded by academic success, professional achievement or the ability to hyperfocus;

• a disorder that always looks the same in children and adults, or in men and women.

ADHD can also coexist with strengths

People with ADHD may describe creativity, rapid associative thinking, energy, humour, curiosity, persistence when highly engaged, willingness to take action and strong performance in fast-moving environments. These are not diagnostic features and they do not cancel out impairment. A strengths-based account should recognise both capability and cost.

3. How ADHD can present across the lifespan

Life stage	Common presentations	What can be missed
Childhood	Distractibility, restlessness, impulsive behaviour, forgetfulness, inconsistent schoolwork, emotional outbursts.	Quiet/inattentive children; girls; high-ability children; difficulties masked by strong family structure.
Adolescence	Poor organisation, procrastination, sleep delay, risk taking, missed deadlines, conflict, variable attainment.	Symptoms attributed only to anxiety, mood, “teenage behaviour” or lack of effort.
Adulthood	Time blindness, task initiation problems, unfinished projects, disorganisation, impulsive spending, job changes, relationship strain, internal restlessness.	People who compensate through overwork, perfectionism, high structure or a partner/assistant doing executive tasks.
Later life	Persistent executive difficulties may interact with retirement, bereavement, reduced structure, physical illness, sleep disturbance or cognitive change.	Assuming every attention or memory complaint is ADHD; new cognitive symptoms require assessment for other causes.

4. Diagnosis and assessment

In the UK, NICE recommends that ADHD diagnosis should be made by an appropriately trained healthcare professional with expertise in ADHD, based on a full clinical and psychosocial assessment, developmental and psychiatric history, observer reports where available, and assessment of symptoms and impairment across settings.

A robust assessment usually considers:

• current symptoms of inattention and hyperactivity/impulsivity, with examples rather than checklist scores alone;

• evidence that relevant symptoms were present in childhood, generally before age 12 under DSM-5 criteria;

• impairment in at least two important settings or domains;

• school history, work history, relationships, driving, finances and day-to-day executive functioning;

• mental health, substance use, sleep, physical health, medication and developmental history;

• autism, learning disorders, language or motor-coordination difficulties where relevant;

• alternative explanations such as anxiety, depression, bipolar disorder, trauma, sleep disorders, thyroid disease, medication effects or substance use;

• risk, safeguarding and vulnerabilities, including impulsive behaviour, exploitation, accidents, self-harm or problematic substance use.

Questionnaires are supporting evidence — not a diagnosis.

ASRS, DIVA-5, BAARS, CAARS and other structured tools can improve consistency, but scores must be interpreted within a full clinical assessment. Computerised tests such as QbTest can add objective information in selected settings; they do not independently confirm or exclude ADHD.

5. How common is ADHD?

The NHS England ADHD Taskforce summarises the best research as suggesting ADHD affects roughly 5% of children and around 2–3% of adults. Adult prevalence estimates vary depending on whether studies require evidence of childhood onset and clinically significant impairment. A large global meta-analysis estimated persistent adult ADHD at about 2.6%.

Recognition in healthcare records has historically been substantially lower than expected population prevalence in England, particularly among adults and women. The 2025–26 NHS England work therefore describes ADHD as both under-recognised and under-treated while services simultaneously face rapidly rising referral demand.

Rising diagnosis does not automatically mean overdiagnosis.

More people seeking assessment can reflect improved awareness, recognition of adult and female presentations, reduced stigma, changing service access and previously unmet need. At the same time, high-quality assessment remains essential because attention problems are non-specific and can arise from many causes.

6. Brain networks, dopamine, noradrenaline and genetics

ADHD is highly heritable and genetically complex. It is influenced by many common genetic variants of very small effect together with rarer variants and environmental/developmental factors. There is no single “ADHD gene”, and genetic testing is not used to diagnose routine ADHD.

At a brain-systems level, research implicates distributed networks involved in executive control, reward, salience, timing and default-mode regulation, including prefrontal, striatal, cerebellar and large-scale cortical networks. Group-level differences are real but overlap substantially with people without ADHD.

Dopamine and noradrenaline are particularly important to attention, arousal, motivation and executive control. Stimulant medicines alter catecholamine signalling and can improve the signal-to-noise and regulation of these networks. It is more accurate to describe ADHD as altered regulation across interacting systems than as a simple chemical deficiency.

7. Executive function, motivation and emotional regulation

Working memory

Holding information in mind long enough to use it: instructions, intentions, intermediate steps and mental arithmetic.

Inhibitory control

Pausing before responding, resisting distraction, interrupting less and avoiding impulsive decisions.

Task initiation

Starting important tasks without needing crisis-level urgency or novelty to generate momentum.

Time regulation

Estimating duration, sensing deadlines, transitioning between tasks and acting on future consequences.

Reward sensitivity

Performance can vary markedly according to immediacy, novelty, interest and perceived reward.

Emotional regulation

Rapid frustration, impatience or emotional intensity are common clinical experiences, although emotional dysregulation is not itself a DSM core criterion.

The popular term “rejection sensitive dysphoria” (RSD) describes intense distress around perceived rejection or criticism. Many people with ADHD find the concept useful, but RSD is not a formal DSM-5 or ICD-11 diagnosis and does not currently have a universally accepted diagnostic definition. Clinicians should consider emotional dysregulation, anxiety, trauma, mood disorders and interpersonal context rather than assuming all rejection-related distress is a distinct ADHD syndrome.

8. ADHD rarely exists in isolation

Coexisting conditions are common, but exact percentages vary widely by age, sex, referral setting, diagnostic method and whether the sample is community-based or clinical. For an introductory resource, broad clinical patterns are more useful than treating one prevalence figure as universal.

Area	Common overlaps	Why it matters
Mental health	Anxiety disorders, depression, trauma-related difficulties, OCD; bipolar disorder is an important differential/coexisting diagnosis.	Symptoms can mimic or amplify ADHD; treatment sequencing may matter.
Neurodevelopment	Autism, dyslexia, developmental coordination disorder/dyspraxia, dyscalculia, tic disorders/Tourette syndrome.	A single diagnosis may not explain the full pattern of need.
Sleep	Delayed sleep timing, insomnia, restless legs, sleep apnoea and irregular schedules.	Poor sleep can markedly worsen attention, memory and emotional control.
Eating and weight	Binge-eating patterns, disordered eating and obesity are over-represented in ADHD populations.	Impulsivity, reward, routines, sleep and medication can all interact.
Substance use	Nicotine, alcohol, cannabis and other drug problems occur more often in ADHD groups than in the general population.	Requires direct assessment; appropriately treated ADHD does not equal “giving stimulants to addiction”.
Physical health	Accidents/injury, obesity and some cardiometabolic problems are more frequent at group level.	Lifestyle, access to care, sleep, impulsivity and medication monitoring all matter.

9. ADHD and sleep

Sleep problems are common in ADHD and can substantially worsen attention, emotional regulation, memory, motivation and daytime functioning. Difficulties may include delayed sleep timing, trouble switching off, insomnia, inconsistent routines, restless sleep or excessive daytime sleepiness.

Sleep should be assessed rather than assumed to be “just ADHD”. Consider obstructive sleep apnoea, restless legs, circadian-rhythm disorders, anxiety, depression, substance use, caffeine, medication timing and other medical causes.

Practical principles

• Keep wake time as consistent as possible, including at weekends.

• Use morning daylight and daytime activity to help anchor circadian rhythm.

• Reduce late caffeine, nicotine and stimulating screen use; avoid using alcohol or cannabis as a routine sleep treatment.

• Create a deliberate wind-down sequence rather than waiting to feel naturally sleepy.

• Review timing and duration of ADHD medication if sleep worsens after treatment begins.

• Melatonin can be useful for selected circadian or sleep-onset problems, particularly in children and young people, but should be used with clinical guidance rather than treated as a universal ADHD sleep remedy.

• Seek assessment for persistent snoring, witnessed apnoea, severe daytime sleepiness, restless legs or chronic insomnia.

10. ADHD, substance use and behavioural addictions

ADHD is associated with increased risk of nicotine dependence, alcohol and other substance-use disorders. Mechanisms are likely to include impulsivity, reward sensitivity, emotional regulation difficulties, social adversity, sleep disruption, coexisting conduct problems and attempts to self-manage distress or arousal.

Behavioural problems such as problematic gambling, gaming, shopping or compulsive online behaviour may also occur. These are not inevitable consequences of ADHD and should be assessed on their own terms.

Medication and addiction require nuance.

A history of substance misuse does not automatically rule out ADHD medication. Assessment should consider current stability, diversion risk, cardiovascular and psychiatric safety, formulation choice and monitoring. Long-acting preparations are often preferred where misuse or diversion is a concern. Treatment decisions should be individualised by an experienced prescriber.

11. Treatment: what actually helps

Good ADHD care is multimodal. The balance depends on age, severity, preferences, coexisting conditions and functional goals. For adults, medication has the strongest short-term evidence for reducing core ADHD symptoms, while psychological and skills-based interventions can improve coping, organisation and functioning.

Psychoeducation

Understanding ADHD, impairment, strengths, treatment choices, sleep, driving, work and relationships.

Medication

Stimulant or non-stimulant treatment when clinically indicated, with titration and monitoring.

CBT / psychological work

Targeting procrastination, organisation, cognitive patterns, emotional regulation and coexisting anxiety or depression.

Coaching / skills support

Practical systems for planning, prioritisation, accountability, transitions and routines.

Environmental adjustment

Reducing distraction, externalising reminders, reasonable adjustments, predictable structure and assistive technology.

Health foundations

Sleep, physical activity, nutrition, substance-use review and management of other medical or mental health conditions.

A 2025 Lancet Psychiatry network meta-analysis of 113 adult ADHD randomised trials found the clearest short-term symptom benefits for pharmacological treatments, while psychological therapies also showed benefit on several outcomes. Evidence quality and longer-term functional outcomes vary by intervention, so treatment should be judged by meaningful real-world improvement, not symptom scores alone.

12. Medication overview and safety

Class	Examples used in UK practice	General role	Key monitoring themes
Methylphenidate	Immediate- and modified-release methylphenidate preparations	Common first-line stimulant option, depending on age and guideline pathway.	Blood pressure, pulse, appetite/weight, sleep, mood, side effects, adherence and misuse/diversion risk.
Amphetamine-based	Lisdexamfetamine; dexamfetamine in selected circumstances	Common stimulant option in adults and in guideline-directed switching.	As above; review duration of effect and rebound as well as cardiovascular and psychiatric tolerability.
Atomoxetine	Atomoxetine	Non-stimulant option; takes longer to build effect than stimulants.	Blood pressure/pulse, side effects, mood; review interactions and liver-related warning symptoms.
Guanfacine	Guanfacine modified release	UK use is primarily in children/young people; adult use requires specialist consideration and is not routine NICE adult treatment.	Blood pressure, pulse, sedation; taper rather than abruptly stopping.

Before and during treatment

• Review physical and mental health, current medicines, substance use, cardiovascular history and family history.

• Record baseline weight and relevant cardiovascular observations; obtain further cardiac assessment when clinically indicated rather than routinely ordering ECGs for everyone.

• Titrate against both benefit and adverse effects. The aim is the lowest dose that produces worthwhile functional improvement with acceptable tolerability.

• Monitor blood pressure, pulse, weight/appetite, sleep, mood and emerging adverse effects at clinically appropriate intervals.

• Discuss controlled-drug storage, travel, supply interruptions and diversion risk where stimulants are prescribed.

• Medication should be reviewed periodically; a diagnosis does not automatically mean lifelong medication at an unchanged dose.

2026 evidence update

A 2026 Lancet Psychiatry dose-effect network meta-analysis reinforces that dose optimisation matters: under-dosing can limit benefit, while higher doses do not simply produce proportionally greater efficacy and may increase adverse effects. Titration should therefore be individual and outcome-focused.

13. Psychological, coaching and environmental support

Non-medication support is not a consolation prize and medication is not a substitute for skills or environmental fit. Many people need both. Useful interventions are concrete, externally structured and linked to actual impairment.

• Break tasks into visible next actions rather than broad intentions.

• Externalise working memory: calendars, timers, written checklists, visual boards and automated reminders.

• Use body-doubling or accountability for task initiation when helpful.

• Reduce friction: keep frequently used items visible and create fixed homes for essentials.

• Use protected focus blocks with notifications and competing stimuli reduced.

• Build transition time into the day; lateness often begins with unrealistic assumptions about switching tasks.

• At work or university, consider written instructions, quieter workspace, flexible scheduling, assistive software, structured supervision and regular check-ins.

• CBT adapted for ADHD can target procrastination, planning, unhelpful beliefs and emotional regulation.

14. Women, hormones and later recognition

Females are less likely than males to receive an ADHD diagnosis in childhood and are often diagnosed later. Contributing factors include less disruptive presentation, inattentive symptoms, compensatory behaviour or masking, referral bias and diagnostic overshadowing by anxiety or depression.

Hormonal transitions are an increasingly important area of ADHD research. Some women report changes in ADHD symptoms, mood or medication response across the menstrual cycle, pregnancy/postpartum and perimenopause/menopause. Evidence is developing and individual variability is substantial; symptom tracking can be useful when a reproducible pattern is suspected.

Do not equate “high functioning” with low impairment.

A person may maintain work, parenting or academic performance through extreme effort, perfectionism, sleep sacrifice, anxiety-driven overcompensation or extensive support from others. Assessment should ask what functioning costs, not only whether outcomes look successful from the outside.

15. ADHD in later life

ADHD can persist into older adulthood, although the evidence base is smaller than for younger adults. Later-life assessment requires particular care because sleep disorders, depression, anxiety, medication effects, vascular disease and neurocognitive disorders can all produce attention or memory problems.

A convincing ADHD diagnosis in later life still requires a developmental history consistent with childhood onset. New-onset executive or memory deterioration should not simply be labelled ADHD.

16. ADHD care in England: the 2026 picture

The independent NHS England ADHD Taskforce published Part 1 in June 2025 and its final Part 2 report in November 2025; the NHS publication page was updated in February 2026. The Taskforce describes major unmet need, very long waits in some areas, inconsistent pathways and historically low clinical recognition relative to expected prevalence.

Key direction of travel

• treat ADHD as a common condition rather than a niche service problem;

• reduce waiting times and simplify fragmented pathways;

• offer needs-based practical support before, during and after diagnostic assessment rather than making all help contingent on a diagnosis;

• improve training, data quality and coordination across health, education, employment and justice;

• develop more efficient and digitally enabled models of care while maintaining diagnostic quality and safety;

• strengthen roles across neighbourhood and primary-care systems where appropriate, supported by specialist expertise.

Important UK distinction

Access routes, commissioning and shared-care arrangements vary across England, Scotland, Wales and Northern Ireland. Even within England, local policies differ. Check current local NHS and Integrated Care Board arrangements rather than assuming one national pathway operates identically everywhere.

17. Practical support at work, study and home

At work

• Ask for instructions and priorities in writing where possible.

• Use shorter deadlines or staged milestones for long projects.

• Consider a quieter workspace, headphones, hybrid working or protected focus periods where compatible with the role.

• Schedule brief, predictable supervision/check-ins rather than relying on crisis escalation.

• Access to Work may fund eligible workplace support in Great Britain.

At university or college

• Contact disability/student-support services early; evidence requirements vary.

• Explore study-skills support, assistive technology, recording tools, exam adjustments and deadline planning.

• Build a weekly study structure around wake time and fixed commitments rather than motivation alone.

At home

• Share plans visibly rather than relying on verbal reminders.

• Use one trusted calendar and one capture system for tasks.

• Automate recurring bills and reminders where safe.

• Create “landing zones” for keys, medication, wallet and other essentials.

• Discuss division of labour explicitly; invisible executive tasks can become a major source of relationship conflict.

18. Screening tools: useful, but not diagnostic

Screening questionnaires can flag areas that deserve assessment, but they cannot establish ADHD, addiction or another diagnosis. Results are especially vulnerable to false positives when sleep, anxiety, depression, trauma, substance use or acute stress are present.

Purpose	Examples	Use with caution
Adult ADHD	ASRS v1.1 / ASRS-5; structured interviews such as DIVA-5	Positive screening means “assess further”, not “diagnosed”.
Alcohol	AUDIT-C/AUDIT; CAGE is brief but less comprehensive	Ask quantity, frequency, dependence features, withdrawal and harms.
Gambling	NODS-CLiP or other validated gambling screens	Interpret alongside financial, occupational and relational impact.
Gaming / online behaviour	Validated disorder-specific tools where appropriate	High use is not automatically addiction; impairment and loss of control matter.

19. Video library — all links in one place

The original Neurohaven page embedded videos throughout the page. They are consolidated here so readers can browse them without interrupting the main clinical information. External videos are for education and lived-experience perspectives; inclusion does not imply that every statement in a video represents Neurohaven clinical guidance.

Video	Focus	Link
Ain’t No Shame in My ADHD Brain — Torrian Timms, TEDxDeepEllum	Lived experience / stigma	Open video
ADHD brain chemistry	Neuroscience explainer	Open video
Take My Hand — a child’s perspective of ADHD	Lived experience	Open video
Inattentive ADHD	Presentation / recognition	Open video
Is medication worth it? — video 1	Medication discussion	Open video
Is medication worth it? — video 2	Medication discussion	Open video
Full clinical lecture — approximately 1 hour	Long-form clinical education	Open video
Rejection sensitivity / ‘RSD’	Emotional regulation / lived experience	Open video
Have you got both?	Coexisting neurodevelopmental conditions	Open video

20. Trusted ADHD resources

21. Key references and further reading

1. NICE. Attention deficit hyperactivity disorder: diagnosis and management (NG87). Current online guideline. Link

2. NHS England. Report of the independent ADHD Taskforce: Part 1. Published 20 June 2025. Link

3. NHS England. Report of the independent ADHD Taskforce: Part 2. Published 6 November 2025. Link

4. NHS England. Plain English summary of the ADHD Taskforce report. Published 9 December 2025. Link

5. Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818. Link

6. Song P, et al. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health. 2021;11:04009. Link

7. Ostinelli EG, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: systematic review and component network meta-analysis. Lancet Psychiatry. 2025;12(1):32–43. Link

8. Nourredine M, et al. Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Lancet Psychiatry. 2026;13(6):485–495. Link

9. Martin J. Why are females less likely to be diagnosed with ADHD in childhood than males? Lancet Psychiatry. 2024;11(4):303–310. Link

10. Agnew-Blais JC. Hidden in plain sight: delayed ADHD diagnosis among girls and women. J Child Psychol Psychiatry. 2024;65(10):1398–1400. Link

11. Brikell I, et al. ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases. Lancet Psychiatry. 2024;11(1):16–26. Link

Editorial note

This document is an educational overview, not a substitute for a full clinical guideline. Evidence is updated to August 2026 where practical. External links and video availability can change. Neurohaven does not control third-party content.

Neurohaven.co.uk • ADHD Essential Information & Support • Updated August 2026

ADHD - Essential info